drugset / Trial / NCT01408342

Alemtuzumab and Rituximab in Aplastic Anemia

NCT01408342

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the efficacy of combination of alemtuzumab and rituximab as first line therapy in aplastic anemia.

Timeline

Start
2011-07
Primary completion
2013-01
Completion
2014-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Alemtuzumab Monoclonal antibody 5 mg/m2 Subcutaneous
Subject Alemtuzumab Monoclonal antibody 10 mg Subcutaneous
Subject Rituximab Monoclonal antibody 50 mg/m2 Intravenous
Subject Rituximab Monoclonal antibody 100 mg Intravenous

Indications